Beta-Blockers in High-Risk Outpatients with Chronic Obstructive Pulmonary Disease are Associated with All-Cause Mortality – The STATUETTE Cohort Study

Beta-Blockers in High-Risk Outpatients with Chronic Obstructive Pulmonary Disease are Associated with All-Cause Mortality – The STATUETTE Cohort Study

Mathias Damkjær,1 Charlotte Suppli Ulrik,1,2 Nina Godtfredsen,1,2 Kjell EJ Håkansson1 1Department of Respiratory Medicine, Copenhagen University Hospital - Hvidovre, Hvidovre, Denmark; 2Institute of Clinical Medicine, University of Copenhagen, Copenhagen, DenmarkCorrespondence: Kjell EJ HåkanssonDep...

Full description

Bibliographic Details
Main Authors:	Damkjær M, Suppli Ulrik C, Godtfredsen N, Håkansson KEJ
Format:	Article
Language:	English
Published:	Dove Medical Press 2021-08-01
Series:	International Journal of COPD
Subjects:	chronic obstructive pulmonary disease cardiovascular disease exacerbations beta-blockers mortality
Online Access:	https://www.dovepress.com/beta-blockers-in-high-risk-outpatients-with-chronic-obstructive-pulmon-peer-reviewed-fulltext-article-COPD

Similar Items

Statins in High-Risk Chronic Obstructive Pulmonary Disease Outpatients: No Impact on Time to First Exacerbation and All-Cause Mortality – The STATUETTE Cohort Study
by: Damkjær M, et al.
Published: (2021-03-01)

Statins in High-Risk Chronic Obstructive Pulmonary Disease Outpatients: No Impact on Time to First Exacerbation and All-Cause Mortality – The STATUETTE Cohort Study [Corrigendum]
by: Damkjær M, et al.
Published: (2021-08-01)

Effect of beta-blockers on exacerbation rate and lung function in chronic obstructive pulmonary disease (COPD)
by: Sean Duffy, et al.
Published: (2017-06-01)

Beta-blocker under-use in COPD patients
by: Lim KP, et al.
Published: (2017-10-01)

Impact of beta‐blocker use on the long‐term outcomes of heart failure patients with chronic obstructive pulmonary disease
by: Yoshiaki Kubota, et al.
Published: (2021-10-01)

Characteristics of Beta-blocker Treatment in Cardiac Patients with Concomitant Chronic Obstructive Pulmonary Disease
by: Frigy Attila, et al.
Published: (2016-12-01)

The association between beta-blocker use and chronic obstructive pulmonary disease risk, severity, and exacerbation
by: Hemin Khalid Saber
Published: (2021-01-01)

Comparison of Long-Term Clinical Implications of Beta-Blockade in Patients With Obstructive Airway Diseases Exposed to Beta-Blockers With Different β1-Adrenoreceptor Selectivity: An Italian Population-Based Cohort Study
by: Maurizio Sessa, et al.
Published: (2018-10-01)

Beta-blockers, and real clinical practice in Russia: the gap between the understanding of the doses of beta-blockers and subsequent prognosis in patients with cardiovascular disease
by: I V Fomin, et al.
Published: (2017-12-01)

Beta-blockers, and real clinical practice in Russia: the gap between the understanding of the doses of beta-blockers and subsequent prognosis in patients with cardiovascular disease
by: Fomin I.V., et al.
Published: (2017-09-01)

Beta-blockers in Cardiovascular Therapy: A Review
by: Camelia C. Diaconu, et al.
Published: (2019-10-01)

Beta-blockeRs tO patieNts with CHronIc Obstructive puLmonary diseasE (BRONCHIOLE) – Study protocol from a randomized controlled trial
by: Josefin Sundh, et al.
Published: (2020-01-01)

THE BISOPROLOL — A HIGH SELECTIVE BETA-BLOCKER ACCORDING TO EVIDENCE BASED MEDICINE
by: Yu. V. Lukina, et al.
Published: (2016-01-01)

Ischemic Heart Disease during Acute Exacerbations of COPD
by: Rosa Malo de Molina, et al.
Published: (2018-09-01)

Chronic obstructive pulmonary disease exacerbation. Do we use all possibilities of outpatient therapy?
by: I V Leshchenko
Published: (2013-10-01)

Study of Sputum Bacteriology of Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease
by: Shaila Jay Shah, et al.
Published: (2021-04-01)

Beta-blockers after myocardial infarction: Are they useful to all patients? And how long should be the beta-blocker therapy?
by: Roberto F.E. Pedretti
Published: (2018-06-01)

Long-term effects of beta-blocker use on lung function in Japanese patients with chronic obstructive pulmonary disease
by: Oda N, et al.
Published: (2017-04-01)

Beta-blockers in modern glaucoma therapy. Review
by: O. A. Kiseleva, et al.
Published: (2014-07-01)

Beta-blockers in modern glaucoma therapy. Review
by: O. A. Kiseleva, et al.
Published: (2014-07-01)

Pre-Clinical Investigation of Cardioprotective Beta-Blockers as a Therapeutic Strategy for Preeclampsia
by: Natalie K. Binder, et al.
Published: (2021-07-01)

The evaluation of β-adrenoceptor blocking agents in patients with COPD and congestive heart failure: a nationwide study
by: Liao KM, et al.
Published: (2017-08-01)

Intravenous ephedrine abolished suspected bronchoconstriction during general anesthesia in a patient undergoing beta-adrenergic blocker therapy for hypertension
by: Hiroyuki Oshika, et al.
Published: (2019-01-01)

PRACTICE OF PRESCRIBING BETA-BLOCKERS AND ITS COMPLIANCE WITH CLINICAL GUIDELINES ACCORDING TO TWO REGISTERS OF CARDIOVASCULAR DISEASES
by: S. Yu. Martsevich, et al.
Published: (2016-06-01)

Efficacy of beta-blockers in the treatment of sepsis
by: Peng Jin, et al.
Published: (2021-01-01)

Beta-Blockers and Cancer: Where Are We?
by: Rita Peixoto, et al.
Published: (2020-05-01)

ENDOTHELIAL DYSFUNCTION AND ROLE NITRATES AND BETA-BLOCKERS IN ITS CORRECTION IN ISCHEMIC HEART DISEASE
by: A. N. Britov
Published: (2016-05-01)

THE ROLE OF VASODILATING BETA-BLOCKERS IN PATIENTS WITH HYPERTENSION AND THE CARDIOMETABOLIC SYNDROME
by: A. A. Taylor, et al.
Published: (2011-08-01)

NEBIVOLOL: A THIRD GENERATION BETA BLOCKER AS ANTIHYPERTENSION AGENT
by: Ni Putu Wirantari, et al.
Published: (2013-07-01)

Pre-operative beta-blocker therapy does not affect short-term mortality after esophageal resection for cancer
by: Souheil Reda, et al.
Published: (2020-12-01)

Inflammation and infections in unreported chronic obstructive pulmonary disease exacerbations
by: Calderazzo MA, et al.
Published: (2019-04-01)

Risk of Chronic Obstructive Pulmonary Disease Exacerbation in Patients Who Use Methotrexate—A Nationwide Study of 58,580 Outpatients
by: Christina Marisa Bergsøe, et al.
Published: (2021-05-01)

Neuropsychiatric Consequences of Lipophilic Beta-Blockers
by: Sabina Alexandra Cojocariu, et al.
Published: (2021-02-01)

Comparative effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on the risk of pneumonia and severe exacerbations in patients with COPD
by: Lai CC, et al.
Published: (2018-03-01)

Beta-blockers in Prevention of Development of Varices and Variceal Bleeding in Cirrhosis: Current Management, Controversies, and Future Directions
by: Dhiraj Tripathi
Published: (2017-06-01)

Beta-blocker use and COPD mortality: a systematic review and meta-analysis
by: Etminan Mahyar, et al.
Published: (2012-09-01)

Impact of overweight and obesity on acute exacerbations of COPD – subgroup analysis of the Taiwan Obstructive Lung Disease cohort
by: Wei YF, et al.
Published: (2017-09-01)

Could beta blocker use in elderly hypertensive patients reduce risk of skin cancers?
by: Erdinc Terzi, et al.
Published: (2019-12-01)

Investigation serum procalcitonin in patients with exacerbation of obstructive pulmonary disease
by: Mina Delghandi, et al.
Published: (2020-12-01)

Beta adrenergic blockers poisoning
by: Tadić Milorad, et al.
Published: (2016-01-01)